Author Topic: MRF joins forces with NIH in developing MRF-008  (Read 132 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
MRF joins forces with NIH in developing MRF-008
« on: February 02, 2014, 02:38:28 pm »
The Myelin Repair Foundation's president has issued a statement about its collaboration with the National Institute of Neurological Disorders and Stroke, a division of the National Institutes of Health (NIH), about advancing  new generic drug compound now being called MRF-008.

Quote
This compound—which we will refer to as MRF-008—is a generic drug our academic research consortium has identified as a potential candidate to protect and repair myelin in MS patients. Since MRF-008 is already FDA-approved for another disease indication, the MRF and the NIH see a tremendous opportunity to investigate the repurposing of this drug to protect and repair myelin in multiple sclerosis patients.


The statement (January 2014) can be seen in its entirety here.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.